Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

David Epstein emerges at newly named Flagship Pioneering

Flagship Pioneering today announced the appointment of industry veteran David Epstein to serve in the newly created role of Executive Partner. Epstein will join as a strategic resource to the firm that systematically conceives, creates, resources and grows first-in-category ventures … Continue reading

Posted in Executive Appointments, M&A Finance and Funding | Tagged , , , , , , , , | Leave a comment

eFFECTOR Therapeutics Secures New Series B Funding

eFFECTOR Therapeutics, an early-stage company focused on the discovery and development of small molecule cancer therapeutics in San Diego, has secured its Series B financing up to USD 56 million. The new funding came from Sectoral Asset Management, a new … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , , , , , , , , | Leave a comment

Kuros Biosurgery Closes Round at CHF 20m

Kuros Biosurgery AG, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products and focused in therapeutic areas covering sealants and orthobiologics, today announces that it has raised an additional CHF 5 million in a fully subscribed second closing of … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , , | Leave a comment

Boston’s Biotech Women Take Center Stage

The last few days has seen a number of events in the Boston Biotech Cluster which have involved women executives. Here is our pick of the top 5: Annalisa Jenkins: Leads Dimension Therapeutics to an IPO and gets names as … Continue reading

Posted in Board Director Appointments, Executive Appointments, M&A Finance and Funding | Tagged , , , , , , , , | Leave a comment

Biotech Investors Follow Pattern in Funding and Hiring Executives

Written by: Karl Simpson To be blunt, biotechnology ventures require lots of capital, and although alternative funding sources are now more accessible, money has traditionally come from the venture capital firms. These venture firms exercise differing strategies in allocating risk … Continue reading

Posted in Board Director Appointments, Executive Appointments, M&A Finance and Funding, Workplace Diversity | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Audion Therapeutics has Investors Listening

Audion Therapeutics is a Netherlands based biotech developing therapeutics in the area of hearing loss, an area that has garnered serious interest from investors against the backdrop of an ageing population. This investor sentiment has meant that Audion Therapeutics was … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , , , | Leave a comment

Sanofi Genzyme Bioventures announce a brace of deals

Sanofi Genzyme Bioventures announced to financing deals today (Sept 8 – 2015), as it contributed to the financing of Proteostasis Therapeutics, a Series B mezzanine round of $37m to the company developing a cystic fibrosis drug for the orphan disease. … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , | Leave a comment

Selecta Biosciences recruits $38m Series E and CMO

Selecta Biosciences raises $38m in Series E funding and also appoints Earl (‘Skip’) Sands, MD, as Chief Medical Officer (CMO). The company is a clinical stage biotech developing a novel class of targeted antigen-specific immune therapies. Proceeds from the financing … Continue reading

Posted in Executive Appointments, M&A Finance and Funding | Tagged , , , , , , , , , , | Leave a comment

Genmab and Novo Nordisk in bispecific antibody deal

Genmab A/S (OMX: GEN) announced it has entered an agreement to grant Novo Nordisk commercial licenses to use the DuoBody technology platform to create and develop  bispecific antibody candidates for two therapeutic programs.  The bispecific antibodies will target a disease … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , , , | Leave a comment

$40m for rare focused Rhythm

Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap